Sodium Glucose Transporter 2 Inhibitor as a Novel Therapy for Patients with Chronic Hyponatremia
Ibrahim, M., EL Shahawy, E., Elbadawy, A., Rashaad, T., Srour, Z., Mansour, A. (2023). Sodium Glucose Transporter 2 Inhibitor as a Novel Therapy for Patients with Chronic Hyponatremia. EKB Journal Management System, 90(2), 2440-2445. doi: 10.21608/ejhm.2023.286023
Mohamed E. Ibrahim; EL Metwally Lotfy EL Shahawy; Ayman M. Elbadawy; Tayseer Shawky Rashaad; Zeinab Adel Elsayed Ahmed Srour; Ahmed Ezzat Mansour. "Sodium Glucose Transporter 2 Inhibitor as a Novel Therapy for Patients with Chronic Hyponatremia". EKB Journal Management System, 90, 2, 2023, 2440-2445. doi: 10.21608/ejhm.2023.286023
Ibrahim, M., EL Shahawy, E., Elbadawy, A., Rashaad, T., Srour, Z., Mansour, A. (2023). 'Sodium Glucose Transporter 2 Inhibitor as a Novel Therapy for Patients with Chronic Hyponatremia', EKB Journal Management System, 90(2), pp. 2440-2445. doi: 10.21608/ejhm.2023.286023
Ibrahim, M., EL Shahawy, E., Elbadawy, A., Rashaad, T., Srour, Z., Mansour, A. Sodium Glucose Transporter 2 Inhibitor as a Novel Therapy for Patients with Chronic Hyponatremia. EKB Journal Management System, 2023; 90(2): 2440-2445. doi: 10.21608/ejhm.2023.286023

Sodium Glucose Transporter 2 Inhibitor as a Novel Therapy for Patients with Chronic Hyponatremia

The Egyptian Journal of Hospital Medicine
Article 68, Volume 90, Issue 2, January 2023, Page 2440-2445  XML PDF (313.57 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2023.286023
View on SCiNiTO View on SCiNiTO
Authors
Mohamed E. Ibrahim; EL Metwally Lotfy EL Shahawy; Ayman M. Elbadawy; Tayseer Shawky Rashaad; Zeinab Adel Elsayed Ahmed Srour; Ahmed Ezzat Mansour
Abstract
Background: The most prevalent electrolyte anomaly seen in both hospitalised patients and the general population, hyponatremia is often defined as serum sodium concentration 135 mEq/L and is linked to higher morbidity and death.
Objective: To study sodium glucose transporter2 (SGLT2) Inhibitors influence in individuals suffering euvolemic and hypervolemic chronic hyponatremia and it may be a potential new alternative for persistent hyponatremia therapy in non-diabetic and diabetic patients.
Patients and Methods: That prospective research was carried out on 75 chronic euvolemic or hypervolemic hyponatremia individuals admitted to internal medicine department in hospitals of Benha university. 2 groups were formed from participating individuals: 25 hypervolemic hyponatremia or chronic euvolemic individuals in group (1) who received placebo with additional conventional treatment of chronic hyponatremia (fluid restriction). Group (2) included 50 hypervolemic hyponatremia or chronic euvolemic individuals who received SGLT2 inhibitor (empagliflozin).Results: No critical change was seen in serum sodium among day 0 and day 4 or between day 0 and day 30 in SGLT2 inhibitor untreated patients. Serum sodium was critically lower in day 0 than day 4 (p <0.001) and was also substantially lower in day 0 than 30 (p <0.001) in SGLT2 inhibitor treated patients.
Conclusions: The use of SGLT2 inhibitor empagliflozin lead to serum sodium critical elevation in day 4 and 30 after the start of treatment compared to baseline serum sodium level with a higher level at day 4 and 30 than SGLT2 inhibitor untreated patients.
 
Keywords
Novel Therapy; SGLT2 and Chronic Hyponatremia
Statistics
Article View: 164
PDF Download: 300